Agalsidase-Beta Therapy for Advanced Fabry DiseaseMaryam Banikazemi, Robert J. Desnick, Jan Bultas et al.|Annals of Internal Medicine|2007Cited by 565
Treatment of Fabry’s Disease with the Pharmacologic Chaperone MigalastatDominique P. Germain, Raphael Schiffmann, Derralynn Hughes et al.|New England Journal of Medicine|2016Cited by 555
Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry diseaseDominique P. Germain, William R. Wilcox, Robert J. Desnick et al.|Journal of Medical Genetics|2015Cited by 363
Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry RegistryAlberto Ortíz, David G. Warnock, Ademola K. Abiose et al.|Journal of Medical Genetics|2016Cited by 147
Chronic kidney disease and an uncertain diagnosis of Fabry disease: Approach to a correct diagnosisLinda van der Tol, Gabor E. Linthorst, Carla E. M. Hollak et al.|Molecular Genetics and Metabolism|2014Cited by 64